Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dimethyl Sulfoxide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLO1 | Q04760 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.42 |
| ▸ | MEN1 | O00255 | 8/20 | 0.42 |
| ▸ | PAX8 | Q06710 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 6/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.42 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 8/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | MITF | O75030 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL106826 | 0.94 | GLO1 (0.50) | GLO1KMT2AMEN1PAX8LMNA | |
| SCHEMBL106825 | 0.94 | GLO1 (0.50) | GLO1KMT2AMEN1PAX8LMNA | |
| SCHEMBL28279585 | 0.89 | GLO1 (0.46) | GLO1KMT2AMEN1PAX8LMNA | |
| SCHEMBL4450762 | 0.73 | KMT2A (0.57) | KMT2AMEN1LMNAALDH1A1KDM4E | |
| SCHEMBL4450765 | 0.73 | KMT2A (0.57) | KMT2AMEN1LMNAALDH1A1KDM4E | |
| SCHEMBL9341971 | 0.70 | CES2 (0.44) | KMT2AMEN1ALDH1A1KDM4EPOLB | |
| SCHEMBL29754411 | 0.70 | GLO1 (0.41) | GLO1KMT2AMEN1PAX8LMNA | |
| SCHEMBL30306284 | 0.69 | RAB9A (0.44) | KMT2AMEN1LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL23928455 | 0.68 | MITF (0.65) | KMT2AMEN1LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL23928456 | 0.68 | MITF (0.65) | KMT2AMEN1LMNAALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 293 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217966-A1 | PHARMACEUTICAL COMPOSITION CONTAINING GLP-1 RECEPTOR AGONIST HAVING FUSED RING | SHIONOGI & CO., LTD. (JP) | 2024-07-04 | — | — | US | disclosed |
| US-12024519-B2 | Fused ring derivative having MGAT-2 inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2024-07-02 | — | — | US | disclosed |
| EP-4389750-A1 | NUCLEOSIDE DERIVATIVES AND PRODRUGS THEREOF HAVING VIRAL GROWTH INHIBITORY ACTION | Shionogi & Co., Ltd. (JP) | 2024-06-26 | — | — | EP | disclosed |
| EP-3957627-B1 | 6-MEMBERED HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | SHIONOGI & CO (JP) | 2024-06-19 | — | — | EP | disclosed |
| EP-4219508-B1 | SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVE AND PRODRUG THEREOF | SHIONOGI & CO (JP) | 2024-06-05 | — | — | EP | disclosed |
| CN-118119624-A | Nucleoside derivatives and prodrugs thereof having inhibitory effect on viral proliferation | 盐野义制药株式会社 | 2024-05-31 | — | — | CN | disclosed |
| CN-111801330-B | Fused ring compounds having dopamine D3 receptor antagonism | 盐野义制药株式会社 | 2024-04-05 | — | — | CN | disclosed |
| WO-2024063140-A1 | MONOCYCLIC COMPOUND HAVING GLP-1 RECEPTOR AGONIST ACTIVITY | 塩野義製薬株式会社 | 2024-03-28 | — | — | WO | disclosed |
| WO-2024063143-A1 | FUSED RING COMPOUND HAVING GLP-1 RECEPTOR AGONIST EFFECT | 塩野義製薬株式会社 | 2024-03-28 | — | — | WO | disclosed |
| CN-112533922-B | Polycyclic pyridone derivatives | 盐野义制药株式会社 | 2024-03-22 | — | — | CN | disclosed |
| US-20120015961-A1 | ISOTHIOUREA DERIVATIVES OR ISOUREA DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-01-19 | — | — | US | disclosed |
| US-20110319414-A1 | NOVEL TRIAZINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | SHIONOGI & CO., LTD. (JP) | 2011-12-29 | — | — | US | disclosed |
| EP-2399910-A1 | NOVEL TRIAZINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | Shionogi&Co., Ltd. (JP) | 2011-12-28 | — | — | EP | disclosed |
| CN-102186841-A | 2-aminopyrimidin-4-one and 2-aminopyridine derivatives having BACE1 inhibitory activity | SHIONOGI & CO | 2011-09-14 | — | — | CN | disclosed |
| US-20110190279-A1 | SULFUR-CONTAINING HETEROCYCLIC DERIVATIVE HAVING BETA SECRETASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2011-08-04 | — | — | US | disclosed |
| US-20110183939-A1 | NOVEL PYROLINONE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | SHIONOGI & CO., LTD. (JP) | 2011-07-28 | — | — | US | disclosed |
| CN-102119161-A | Sulfur-containing heterocyclic derivatives having beta-secretase inhibitory activity | SHIONOGI & CO | 2011-07-06 | — | — | CN | disclosed |
| EP-2336109-A1 | NOVEL PYRROLINONE DERIVATIVE AND MEDICINAL COMPOSITION CONTAINING SAME | Shionogi&Co., Ltd. (JP) | 2011-06-22 | — | — | EP | disclosed |
| EP-2305672-A1 | SULFUR-CONTAINING HETEROCYCLIC DERIVATIVE HAVING ß-SECRETASE-INHIBITING ACTIVITY | Shionogi & Co., Ltd. (JP) | 2011-04-06 | — | — | EP | disclosed |
| WO-2010114181-A1 | ACRYLAMIDE COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183939-A1 | NOVEL PYROLINONE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | P2RX3, P2RX7, P2RX2 | GLO1 4070/4885KMT2A 2757/4885MEN1 1222/4885 |
| US-20240217966-A1 | PHARMACEUTICAL COMPOSITION CONTAINING GLP-1 RECEPTOR AGONIST HAVING FUSED RING | GLP1R, GIPR, GCGR | GLO1 1371/4885KMT2A 3200/4885MEN1 918/4885 |
| US-20120015961-A1 | ISOTHIOUREA DERIVATIVES OR ISOUREA DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY | BACE1, BACE2, APP | GLO1 1324/4885KMT2A 1656/4885MEN1 3671/4885 |
| US-20110190279-A1 | SULFUR-CONTAINING HETEROCYCLIC DERIVATIVE HAVING BETA SECRETASE INHIBITORY ACTIVITY | BACE1, BACE2, APP | GLO1 529/4885KMT2A 2134/4885MEN1 1637/4885 |
| US-20110319414-A1 | NOVEL TRIAZINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | P2RX3, P2RX5, P2RX2 | GLO1 4748/4885KMT2A 2962/4885MEN1 4352/4885 |
| US-12024519-B2 | Fused ring derivative having MGAT-2 inhibitory activity | MGAT2, MGAT1, ACAT2 | GLO1 299/4885KMT2A 213/4885MEN1 3340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.